IHC of CA19-9 on an FFPE Salivary Gland Tissue

Specification Sheets
Safety Data Sheet


Intended Use For In Vitro Diagnostic Use
Summary and Explanation CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. It was discovered in patients with Colon Cancer and Pancreatic Cancer in 1981. Increased levels of CA19-9 are also found in non-malignant conditions, such as Mirizzi’s Syndrome and diseases of the bile duct and liver. The main use of CA19-9 is to determine whether a pancreatic tumor is secreting it; if that is the case, then the levels should fall when the tumor is treated, and they may rise again if the disease recurs. CA19-9 antigen is highly expressed in Gastrointestinal (gastric, pancreatic, and colonic) Adenocarcinomas and salivary gland Mucoepidermoid Carcinomas. CA19-9 is usually not reactive with breast, kidney, and prostate Carcinomas, but is reactive with sialylated Lea-active pentasaccharide (sialylated lacto-N-fucopentaose II), which is enzymatically synthesized by sialylation of Type 1 carbohydrate chains.
Antibody Type Mouse Monoclonal Clone 121SLE
Isotype IgM Reactivity Paraffin, Frozen
Localization Cytoplasmic Control Breast, Colon, Cervix, Pancreas, Pancreas Cancer, Breast Carcinoma, Colon Carcinoma, Transitional Cell Carcinoma, Ovarian Carcinoma Thyroid Carcinoma
Presentation CA19-9 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Catalog No. Antibody Type Dilution Volume/QTY
BSB 5106 Prediluted Ready-To-Use 3.0 ml
BSB 5107 Prediluted Ready-To-Use 7.0 ml
BSB 5108 Prediluted Ready-To-Use 15.0 ml
BSB 5109 Concentrated 1:100 – 1:500 0.1 ml
BSB 5110 Concentrated 1:100 – 1:500 0.5 ml
BSB 5111 Concentrated 1:100 – 1:500 1.0 ml
BSB 5112 Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.
Related Products